Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

11.44 -0.21 (-1.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,930,006
Open 11.70
Bid (Size) 11.27 (1)
Ask (Size) 11.69 (3)
Prev. Close 11.65
Today's Range 11.38 - 11.74
52wk Range 8.730 - 13.05
Shares Outstanding 692,072,184
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Peering Into Roivant Sciences's Recent Short Interest
Via Benzinga
Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics
From Pulmovant, Inc.
Via GlobeNewswire

Performance

YTD
-5.3%
-5.3%
1 Month
+3.0%
+3.0%
3 Month
+12.7%
+12.7%
6 Month
+5.1%
+5.1%
1 Year
+1.7%
+1.7%

More News

Read More
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
From Roivant Sciences
Via GlobeNewswire
Stocks Edge Higher After Court Stifles Trump Tariffs, Nvidia Rallies To 3-Month Highs, Bitcoin Dips Below $107K: What's Driving Markets Thursday?
Via Benzinga
Topics Government
Roivant Sciences's Earnings Outlook
Via Benzinga
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Earnings Scheduled For May 29, 2025
Via Benzinga
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025
From Roivant Sciences
Via GlobeNewswire
Roivant Sciences Q3 Earnings Assessment
Via Benzinga
Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift
Via Investor's Business Daily
Topics Government
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
From Roivant Sciences
Via GlobeNewswire
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data
Via Benzinga
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.
Via Investor's Business Daily
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
From Roivant Sciences
Via GlobeNewswire
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
From Roivant Sciences
Via GlobeNewswire
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tech Stocks Surge, Steelmakers Jump On Trump's 25% Tariffs, Copper Hits 9-Month Highs: What's Driving Markets Monday?
Via Benzinga
Topics Government World Trade
Roivant Sciences Tops Q3 Expectations
Via The Motley Fool
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Earnings Scheduled For February 10, 2025
Via Benzinga
Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care
From Roivant Sciences
Via GlobeNewswire
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025
From Roivant Sciences
Via GlobeNewswire
Trump Index: 6 Companies Linked to Trump’s Cabinet Worth Watching
Via MarketBeat
Topics Government
Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
From Roivant Sciences
Via GlobeNewswire
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
From Roivant Sciences
Via GlobeNewswire

Frequently Asked Questions

Is Roivant Sciences Ltd. - Common Shares publicly traded?
Yes, Roivant Sciences Ltd. - Common Shares is publicly traded.
What exchange does Roivant Sciences Ltd. - Common Shares trade on?
Roivant Sciences Ltd. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Roivant Sciences Ltd. - Common Shares?
The ticker symbol for Roivant Sciences Ltd. - Common Shares is ROIV on the Nasdaq Stock Market
What is the current price of Roivant Sciences Ltd. - Common Shares?
The current price of Roivant Sciences Ltd. - Common Shares is 11.44
When was Roivant Sciences Ltd. - Common Shares last traded?
The last trade of Roivant Sciences Ltd. - Common Shares was at 07/18/25 04:00 PM ET
What is the market capitalization of Roivant Sciences Ltd. - Common Shares?
The market capitalization of Roivant Sciences Ltd. - Common Shares is 7.92B
How many shares of Roivant Sciences Ltd. - Common Shares are outstanding?
Roivant Sciences Ltd. - Common Shares has 8B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.